Alemtuzumab - MS Research Australia

Alemtuzumab

Alemtuzumab

Administration Route: Infusion
Injection site:
Frequency: Two infusions, 12 months apart
TGA approval date: Dec 2013
PBS listed: Yes
Mechanism of action Lemtrada (alemtuzumab) is a monoclonal antibody that targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS. Alemtuzumab depletes circulating T and B lymphocytes after each treatment course.
%reduction in relapse rate, impact of progression 67% RRR in annual relapes rate,94% RRR for new Gad Lesions, 83% RRR new T2 lesions, 52% RRR disability
Pregnancy Category B2
Safe in Pregnancy Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible.
Breastfeeding (information predominatly from  LACTMED database) No information is available on the clinical use of alemtuzumab during breastfeeding. Because alemtuzumab is a large protein molecule with a molecular weight of 145,454, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant’s gastrointestinal tract. Until more data become available, alemtuzumab should be used with caution or avoided during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during alemtuzumab therapy.
Monitoring requirements You will need to have a blood test and a urine test before starting treatment and every month until 4 years after your last Lemtrada infusion even if you are feeling well and your MS symptoms are under control.
Potential side effects (not a comprehensive list) Secondary autoimmunity, infections, rash, headache, and fever, nasal congestion, nausea, fatigue
Manufacturer Sanofi Genzyme
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search